Blueprint Medicines Corp (NASDAQ:BPMC) announced that it has commenced an underwritten public offering of $125,000,000 million in shares of its common stock. In …
Blueprint Medicines Corp (NASDAQ:BPMC) announced data from its ongoing Phase 1 clinical trial evaluating BLU-285, an investigational medicine for the treatment of patients …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new …
Blueprint Technologies Inc (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced the appointment …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, announced that it has …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, today announced the …
Blueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, and PatientCrossroads, a pioneer …
Blueprint Medicines Corp (NASDAQ:BPMC) announced that it will present new preclinical data demonstrating the potential utility of BLU-285 in a subset of patients with …
